Download PDF
Zentralbl Chir 2003; 128(6 ): 487-492
DOI: 10.1055/s-2003-40622
Originalarbeiten und Übersichten

© Georg Thieme Verlag Stuttgart · New York

Anämie und Erythropoietin in der Intensivmedizin

Anemia and erythropietin in critically ill patientsS. Baginski1 , R. Körner1 , U. Frei1 , K.-U. Eckardt1
  • 1Universitätsklinikum Charité der Humboldt-Universität zu Berlin, Campus Virchow-Klinikum, Medizinische Klinik m. S. Nephrologie und Internistische Intensivmedizin
Further Information

Publication History

Publication Date:
16 July 2003 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die therapeutische Gabe von Blut und Blutkomponenten ist auch heute noch mit potenziellen Nebenwirkungen und Risiken verbunden. Außerdem können Blutkonserven zunehmend nicht mehr in ausreichendem Umfang zur Verfügung gestellt werden. Diese Umstände und die positive Erfahrung der erfolgreichen Behandlung verschiedener Anämieformen mit rekombinantem humanen Erythropoietin (rHuEPO) haben dazu geführt, dass in den letzten Jahren das Interesse an der lange wenig beachteten Anämie des kritisch kranken Patienten stark zugenommen hat. Wie bei der Anämie chronischer Erkrankungen sind die Ursachen der Anämie kritisch kranker Patienten vielfältig: vorbestehende Anämie, Blutverluste, inadäquate endogene Erythropoietinproduktion, verkürzte Erythrozytenlebensdauer, verminderte Eisenverfügbarkeit und eine direkte Hemmung der Erythropoiese durch Zytokine tragen zur Entwicklung dieser Anämie bei. Die Bedeutung der Anämie für Verlauf und Prognose kritisch kranker Patienten ist nicht geklärt, und es gibt bislang keine eindeutigen Empfehlungen für ein optimales Therapiemanagement. rHuEPO hat sich neben Strategien zur Vermeidung von Blutverlusten als attraktive Therapieoption erwiesen, die gegenwärtig in Studien evaluiert wird.

Abstract

The transfusion of red blood cells is still associated with possible adverse effects and a residual risk of transmission of viral and nonviral diseases. In addition, there is an increasing shortage of blood supply worldwide. These two facts together with the success experienced in the treatment of various types of anemia with recombinant human EPO, have recently led to an increasing interest in the anemia of critically ill patients. As in the anemia of chronic diseases there are several reasons that contribute to the development of anemia in patients on intensive care units: pre-existing anemia, blood loss, reduced red cell life span, impaired iron availbility and a direct inhibition of erythropoiesis by inflammatory cytokines. The implications of anemia for the progression and prognosis of critical illness are still unclear and the optimal treatment, including optimal “transfusion triggers” remains controversial. Recombinant human EPO has been proven to be effective in ameliorating the anemia of critical illness in several pilot studies and is currently being tested in larger trials.

Schlüsselwörter

Anämie - Blut - Intensivtherapie - Erythropoietin - Eisen - Entzündung

Key words

Anemia - blood - intensive care - erythropoietin - iron - inflammation

Literatur

  • 1 Abel J, Spannbrucker N, Fandrey J, Jelkmann W. Serum erythropoietin levels in patients with sepsis and aeptic shock.  Eur J Hematol. 1996;  57 359-363
    PubMedGoogle Scholar
  • 2 Anonymous. European best practice guidelines for the management of anaemia in patients with chronic renal failure.  Nephrol Dial Transplant. 1999;  14 (Suppl 5) 1-50
    PubMedGoogle Scholar
  • 3 von Ahsen N, Müller C, Serke S, Frei U, Eckardt K U. Important role of non-diagnostic blood loss and diminished erythropoietic response in anemia of medical intensive care patients.  Crit Care Med. 1999;  27 2630-2639
    PubMedGoogle Scholar
  • 4 von Ahsen N, Müller C, Frei U, Eckardt K U. Iron deficiency in critically illness.  Lancet. 1999;  353 842
    PubMedGoogle Scholar
  • 5 Akahane K, Hosoi T, Urabe A, Kawakami M, Takahu F. Effects of recombinant tumor necrosis factor (rhTNF) on normal human and mouse hematopoietic progenitor cells.  Int Cell Cloning. 1987;  5 16-26
    PubMedGoogle Scholar
  • 6 Alazia M, Colavolpe J C, Botti G. et al . Spoliations sanguiones liees aux prelevements en reanimation: etude preliminare.  Ann Fr Anaesth Reanim. 1996;  15 1004-1007
    PubMedGoogle Scholar
  • 7 Biemsa D H, Van de Wiel A, Begiun Y, Kraijenhaagen R J, Marx J JM. Post-operative erythropoiesis is limited by the inflammatory effect of surgery on iron metabolism.  Eur Clin Invest. 1995;  25 383-389
    PubMedGoogle Scholar
  • 8 Boshkov L K, Tredget E E, Janowska-Wieczorek A. Recombinant human erythropoietin for a Jehova’s witness with anemia of thermal injury.  Am J Hematol. 1991;  37 53-54
    PubMedGoogle Scholar
  • 9 Brines M L, Ghezzi P, Keenan S. et al . Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury.  Proc Natl Acad Sci USA. 2000;  12 10 526-10 531
    PubMedGoogle Scholar
  • 10 Broxmeyer H E, Lu L, Platzer E, Feit C, Juliano L, Rubin B Y. Comparative analysis of the influence of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells.  J Immunol. 1983;  131 1300-1305
    PubMedGoogle Scholar
  • 11 Carlini R G, Rayes A A, Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro.  Kidney Int. 1995;  47 740-745
    CrossrefPubMedGoogle Scholar
  • 12 Casadevall N, Nataf J, Viron B, Kilta A, Kiladjian J J, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier Y, Varet B, Mayeux P. Pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.  New Engl J Med. 2002;  46 469-475
    PubMedGoogle Scholar
  • 13 Chen H C, Tsai J C, Tsai J H, Lai Y H. Recombinant human erythropoietin enhances superoxide production by FMLP-stimulated polymorphnuclear leukocytes in hemodialysis patients.  Kidney Int. 1997;  52 1390-1394
    PubMedGoogle Scholar
  • 14 Corwin H L, Parsonnet K, Gettinger A. Red blood transfusion in the ICU - Is there a reason?.  Chest. 1995;  108 767-771
    CrossrefPubMedGoogle Scholar
  • 15 Corwin H L, Gettinger A, Rodriguez R M, Pearl R G, Gubler D, Enny C. et al . Efficacy of recombinant human erythropoietin in the criticaly ill patient: a randomized double blind placebo controlled trial.  Crit Care Med. 1999;  27 2346-2350
    PubMedGoogle Scholar
  • 16 DeMeester S R, Marsh E E, Gerkin T M, Rodriguez J L. Immediate use of recombinant erythropoietin in a Jehova’s witness following major blunt trauma.  Contemp Surgery. 1994;  45 228-232
    PubMedGoogle Scholar
  • 17 Eckardt K U. Erythropoietin: oxygen dependent control of erythopoiesis and its failure in renal disease.  Nephron. 1994;  67 7-23
    PubMedGoogle Scholar
  • 18 Erslev A J, Besarab A. Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure.  Kidney Int. 1997;  51 622-630
    CrossrefPubMedGoogle Scholar
  • 19 Fandrey J, Huwiler A, Frede S, Pfeilschifter J, Jelkmann W. Distinct signaling pathways mediate phorbol-ester-induced and cytokine-induced inhibition of erythropoietin gene expression.  Eur J Biochem. 1996;  226 335-340
    PubMedGoogle Scholar
  • 20 Ferguson B J, Skikne B S, Simpson K M, Bynes R D, Cook J D. Serum transferrin receptor distinguishes the anemia of chronic disease from iron deficiency anemia.  J Lab Clin Med. 1992;  119 385-390
    PubMedGoogle Scholar
  • 21 Fitzgerald R D, Martin C M, Dietz G E. et al . Transfusing red blood cells stored in citrate phosphate dextrose adenin-1 for 28 days fails to improve tissue oxygenation in rats.  Crit Care Med. 1997;  25 726-732
    PubMedGoogle Scholar
  • 22 Fleming R YD, Herndon D N, Vaidya S. et al . The effect of erythropoietin in normal healthy volunteers and pediatric patients with burn injuries.  Surgery. 1992;  112 424-432
    PubMedGoogle Scholar
  • 23 Gabriel A, Kozek S, Chiari A, Fitzgerald R, Grabner C, Geissler K. et al . High-does recombinent human erythropoietin stimulates reticulocyte production in patients with multiple organ dysfunction syndrome.  J Trauma. 1998;  44 363-367
    PubMedGoogle Scholar
  • 24 Hadfield R J, Sinclair D G, Holudsworth P E. et al . Effects of enteral and parenteral nutrition on gut mucosal permeability in the critically ill.  Am J Resp Crit Care Med. 1995;  152 1545-1548
    CrossrefPubMedGoogle Scholar
  • 25 Hebert P C, Wells G, Tweeddale M, Martin C, Marshall J, Pham B. et al . Does transfusion practice affect mortality in critically ill patients?.  Am J Resp Crit Care Med. 1997;  155 1618-1623
    PubMedGoogle Scholar
  • 26 Hebert P C, Wells G, Blajchman M A, Marshall J, Martin C, Pagliarelo G. et al . A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care.  N Engl J Med. 1999;  340 409-417
    CrossrefPubMedGoogle Scholar
  • 27 Hellwig-Bürgel T, Rutkowski K, Metzen E, Fandrey J, Jelkmann W. Interleukin-1 beta and tumor necrosis factor-alpha stimulate DNA binding of hypoxia-inducible factor-1.  Blood. 1999;  94 (5) 1561-1567
    PubMedGoogle Scholar
  • 28 van Iperen C E, Gaillard C AJM, Kraaijenhagen R J, Braam B G, Marx J JM, Van de Wiel A. Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients.  Crit Care Med. 2000;  288 2773-2778
    PubMedGoogle Scholar
  • 29 Jelkmann W, Pagel H, Wolff M, Fandrey J. Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys.  Life Sciences. 1992;  50 301-308
    PubMedGoogle Scholar
  • 30 Jongen-Lavrencic M, Peeters H RM, Rozemuller H, Rombouts W JC, Martens A CM, Vreugdenhil G. et al . IL-6 induced aneamia in rats: possible pathogenic implications for aneamia observed in chronic inflammations.  Clin Exp Immunol. 1996;  103 328-334
    CrossrefPubMedGoogle Scholar
  • 31 Jurado R L. Iron, infections and anemia of inflammation.  Clin Infect Dis. 1997;  25 888-895
    PubMedGoogle Scholar
  • 32 Krafte-Jacobs B, Levetown M L, Bray G L, Ruttimann U E, Pollack M M. Erythropoietin response in critical illness.  Crit Care Med. 1994;  22 821-826
    PubMedGoogle Scholar
  • 33 Krantz S B. Pathogenesis and treatment of the anemia of chronic disease.  Am J Med Sci. 1994;  307 353-359
    PubMedGoogle Scholar
  • 34 Koestner J A, Nelson L D, Morris J A, Safcsak K. Use of recombinant human erythropoietin (r-HuEPO) in a Jehova’s witness refusing transfusion of blood products: case report.  J Trauma. 1990;  30 1406-1408
    PubMedGoogle Scholar
  • 35 Law E J, Still J M, Gattis C S. The use of erythropoietin in two burned patients who are Jehova’s witnesses.  Burns. 1991;  17 75-77
    CrossrefPubMedGoogle Scholar
  • 36 Macdougall I C, Cooper A. The inflammatory response and epoetin sensitivity.  Nephrol Dial Transplant. 2002;  17 (Suppl 1) 48-52
    PubMedGoogle Scholar
  • 37 Marik P E, Sibbald W J. Effects of stored-blood transfusions on oxygen delivery in patients with sepsis.  JAMA. 1989;  269 3024-3029
    PubMedGoogle Scholar
  • 38 Maury C PJ, Andersson L C, Teppo AM; Partanen S, Juvonen M. Mechanism of anemia in rheumatoid arthritis: deminstration of raised interlukin 1 beta concentrations in anemic patients and of interleukin 1 mediated suppression of normal erythropoiesis and proliferation of human erythroleukemia (HEL) cells in vivo.  Ann Rheum Dis. 1988;  47 972-978
    PubMedGoogle Scholar
  • 39 Moghtader J C, Edlich R F, Mintz P D, Zachmann G C, Himel H N. The use of recombinant human erythropoietin and cultured epithelial autografts in a Jehova’s witness with a major thermal injury.  Burns. 1994;  20 176-177
    PubMedGoogle Scholar
  • 40 National kidney f oundation. K/DOQI Clinical practice guidelines for anemia of chronic kidney disease.  Am J Kid Dis. 2001;  37 S182-S238
    PubMedGoogle Scholar
  • 41 Nielsen O J, Thaysen J H. Erythropoietin deficiency in acute renal failure.  Lancet March. 1989;  18 624-625
    PubMedGoogle Scholar
  • 42 Poletes G P, Miller S F, Finley R K, Lincks J. Blood use in the burn unit: a possible role for erythropoietin.  J Burn Care Rehabil. 1994;  15 37-41
    PubMedGoogle Scholar
  • 43 Rogiers P, Zhang H, Leeman M, Nagler J, Neels H, Mélot C. et al . Erythropoietin response is blunted in critically ill patients.  Int Care Med. 1996;  23 159-162
    PubMedGoogle Scholar
  • 44 Schobersberger W, Hobisch-Hagen P, Fuchs D, Hoffmann G, Jelkmann W. Pathogenesis of anemia in critically ill patient.  Clin Intensive Care. 1998;  9 111-117
    PubMedGoogle Scholar
  • 45 Schönhofer B, Wenzel M, Geibel M, Köhler D. Blood transfusion and lung function in chronically anemic patients with severe chronic obstructive pulmonary disease. Crit Care Med 1998; 1824-1828
    Google Scholar
  • 46 Smith S N, Milov D E. Use of erythropoietin in Jehova’s witness children following acute gastrointestinal blood loss.  J Fla Med Assoc. 1993;  80 103-105
    PubMedGoogle Scholar
  • 47 Smoller B R, Kruskall B R. Phlebotomy for diagnostic laboratory tests in adults.  N Engl J Med. 2001;  314 (19) 1233-1235
    PubMedGoogle Scholar
  • 48 Still J M, Belcher K, Law E J, Thompson W, Jordan M, Lewis M. et al . A double-blinded prospective evaluation of recombinant human erythropoietin in acutely burned patients.  J Trauma. 1995;  38 233-236
    PubMedGoogle Scholar
  • 49 Tarpey J, Lawler P G. Iatrogenic anemia? A survey of venesection in patients in the intensive care unit.  Anaesthesia. 1990;  45 396-398
    PubMedGoogle Scholar
  • 50 Vaziri N D, Zhou X J, Smith J. et al . In vivo and in vitro pressor effects of erythropoietin in rats.  Am J Physiol. 1995;  269 F383-F845
    PubMedGoogle Scholar
  • 51 Wagner C, Kurtz A. Der optimale Hämatokrit: Physiologische Betrachtungen.  Klin Wochenschr, Wien. 2001;  113 (Suppl 1) 1-5
    PubMedGoogle Scholar

Prof. Dr. K.-U. Eckardt

Charité, Campus Virchow-Klinikum

Augustenburger Platz 1

13353 Berlin

Phone: 0 30/45 05-5 31 32

Fax: 0 30/45 05-5 39 09

Email: kai-uwe.eckardt@charite.de